Printer Friendly

IntelliPharmaCeutics Ltd. Announces Health Canada Compliance for Its Canadian Operating Affiliate.

TORONTO -- IntelliPharmaCeutics Ltd., a Delaware Corporation (the "Company"), today announced that Health Canada has advised that IntelliPharmaCeutics Corp., the Canadian operating affiliate of the Company, is to be approved for a Compliance rating from Health Canada, following successful inspection of its Toronto testing laboratory premises and procedures by the Health Products and Food Branch Inspectorate.

This rating will permit IntelliPharmaCeutics Corp. to perform drug testing and analysis services on the drug products of its own and of third parties under certified GLP conditions. This represents another major step in the full certification of the testing and manufacturing premises of IntelliPharmaCeutics Corp. as both GLP and cGMP compliant. When that process is complete, IntelliPharmaCeutics Corp. will have total control of the entire drug development process in fully certified facilities right through to the manufacture of clinical and commercial batches of its drug products pipeline. The resultant streamlining of these aspects of drug development will permit the fastest possible market entry for IntelliPharmaCeutics' pipeline and partnered products.

About IntelliPharmaCeutics

IntelliPharmaCeutics is a drug delivery innovator and developer, specializing in the controlled and targeted once-a-day delivery of oral, solid dose pharmaceutical products. It operates from a 25,000 sq ft research laboratory and manufacturing scale-up facility located adjacent to Toronto International Airport. The Company utilizes proprietary, patented and proven drug delivery technologies, to formulate both generic and new drug products with enhanced performance characteristics. In addition to its pre-clinical portfolio, IntelliPharmaCeutics has an extensive pipeline of development products in clinical trials, in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. For more information about IntelliPharmaCeutics, visit the Company's web site at www.intellipharmaceutics.com.

This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of IntelliPharmaCeutics, which may cause actual results, performance or achievements of the Companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future clinical testing and regulatory review will be required prior to marketing approval, there can be no certainty that a successful commercial product will be developed. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration, and intellectual property protections and defenses, are discussed in the Companies' filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The Companies undertake no obligation to update any forward-looking statements.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 30, 2006
Words:434
Previous Article:Osisko Appoints Mr. Staph Leavenworth Bakali to Board of Directors and Reorganizes Management Structure.
Next Article:Viyya Technologies to Introduce eDocVault(TM) Advanced Document Management Software for the Security Industry; Viyya Agrees to Resell and Rebrand...
Topics:


Related Articles
Canada's foreign affiliate rules.
Canadian foreign affiliate rules.
Canadian legislation on foreign investment entities and non-resident trusts.
Withholding under Regulation 105: May 30, 2002.
TEI testimony on pre-budget discussions: November 6, 2002.
Parry Sound Top Employers.
Canadians among finalist for running surgery centres for UK health.
Pre-budget deliberations of House of Commons Standing Committee on Finance: September 8, 2003.
TEI's Testimony before Canadian House of Commons Standing Committee on Finance on pre-budget consultations: September 6, 2005.
TEI testimony on pre-budget consultations before House of Commons Standing Committee on Finance: September 10, 2004.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters